Growth boosts valuation multiples, but it doesn’t always last forever. Companies that cannot maintain it are often penalized with large declines in market value, a lesson ingrained in investors who lost money in tech stocks during 2022.
The risks that can come from buying these assets is precisely why we started StockStory - to isolate the long-term winners from the losers so you can invest with confidence. That said, here are three growth stocks with significant upside potential.
MongoDB (MDB)
One-Year Revenue Growth: +20.9%
Named after "humongous database," reflecting its ability to handle massive data loads, MongoDB (NASDAQ: MDB) provides a flexible document-based database platform that helps developers build, deploy, and maintain modern applications more efficiently.
Why Do We Like MDB?
- Ability to secure long-term commitments with customers is evident in its 25.6% ARR growth over the last year
- Projected revenue growth of 19.8% for the next 12 months suggests its momentum from the last two years will persist
- Free cash flow margin is forecasted to grow by 1.6 percentage points in the coming year, potentially giving the company more chips to play with
MongoDB is trading at $435.78 per share, or 12.8x forward price-to-sales. Is now a good time to buy? Find out in our full research report, it’s free for active Edge members.
Bloom Energy (BE)
One-Year Revenue Growth: +44.5%
Working in stealth mode for eight years, Bloom Energy (NYSE: BE) designs, manufactures, and markets solid oxide fuel cell systems for on-site power generation.
Why Should You Buy BE?
- Annual revenue growth of 19.1% over the past five years was outstanding, reflecting market share gains this cycle
- Free cash flow profile has moved into positive territory over the last five years, showing the company is at an important crossroads
- Rising returns on capital show the company is starting to reap the benefits of its past investments
Bloom Energy’s stock price of $89.95 implies a valuation ratio of 106.8x forward P/E. Is now the right time to buy? See for yourself in our full research report, it’s free for active Edge members.
Natera (NTRA)
One-Year Revenue Growth: +38.2%
Founded in 2003 as Gene Security Network before rebranding in 2012, Natera (NASDAQ: NTRA) develops and commercializes genetic tests for prenatal screening, cancer detection, and organ transplant monitoring using its proprietary cell-free DNA technology.
Why Is NTRA a Good Business?
- Average unit sales growth of 19.6% over the past two years reflects steady demand for its products
- Adjusted operating profits increased over the last two years as the company gained some leverage on its fixed costs and became more efficient
- Free cash flow margin is now positive, indicating the company has passed a significant test
At $233.67 per share, Natera trades at 13x forward price-to-sales. Is now the time to initiate a position? Find out in our full research report, it’s free for active Edge members.
High-Quality Stocks for All Market Conditions
The market’s up big this year - but there’s a catch. Just 4 stocks account for half the S&P 500’s entire gain. That kind of concentration makes investors nervous, and for good reason. While everyone piles into the same crowded names, smart investors are hunting quality where no one’s looking - and paying a fraction of the price. Check out the high-quality names we’ve flagged in our Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 244% over the last five years (as of June 30, 2025).
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today for free. Find your next big winner with StockStory today. Find your next big winner with StockStory today.
